Salesforce, Inc. said on the 18th it will supply AstraZeneca with Agentic artificial intelligence (AI) platform "Agentforce Life Sciences," tailored for the pharmaceutical and biotech industry.
Agentforce Life Sciences is a platform that integrates customer data dispersed across medical and commercial organizations to support personalized customer management and operations. AstraZeneca plans to use it to advance its data- and AI-based management of healthcare professionals (HCPs) and build an integrated customer management system that can be applied across its global business. It also plans to provide tailored experiences for medical staff in key therapeutic areas such as oncology, rare diseases, and cardiovascular, renal, and metabolic diseases.
Salesforce, Inc. will apply MuleSoft Agent Fabric and the open standard Model Context Protocol (MCP) for this rollout. The plan is to link insights across medical, commercial, and field organizations on a single platform and create an environment where frontline staff and AI agents can collaborate seamlessly.
Frank Dipescue, head of Salesforce, Inc.'s life sciences unit, said, "This partnership is the starting point for implementing an agentic customer engagement model in the life sciences industry based on Agentforce Life Sciences," adding, "We will support AstraZeneca in delivering advanced customer experiences and getting innovative therapies to patients faster."
Park Se-jin, head of Salesforce, Inc. Korea, said, "This collaboration shows that AI agents are expanding into a core asset within companies," adding, "In the healthcare industry, where regulatory compliance and data security are critical, we will continue to support the transition to an agentic enterprise and the strengthening of global competitiveness."